HLB Innovation Completes Acquisition of HLB Cell... Aims to Build Domestic Cell Therapy Hub and Expand Across Asia
HLB Innovation has acquired HLB Cell, a company specializing in cell and regenerative medicine, in a move to substantially strengthen its domestic foundation for its cell therapy business. The company will acquire 99.30% of HLB Cell's shares held by HLB Life Science, making HLB Cell a subsidiary. A

HLB Innovation has acquired HLB Cell, a company specializing in cell and regenerative medicine, in a move to substantially strengthen its domestic foundation for its cell therapy business.
The company will acquire 99.30% of HLB Cell's shares held by HLB Life Science, making HLB Cell a subsidiary. According to the company, this acquisition is a strategic business realignment aimed at securing domestic execution capabilities for its global cell therapy business, which has been centered on U.S. subsidiary Verismo Therapeutics, and expanding beyond Korea into Asian markets.
HLB Cell has accumulated cell-related technologies and research capabilities, ranging from the isolation, culture, cryopreservation, and quality assessment of primary cells derived from humans and animals to the production of extracellular matrix based on the culture of normal human cells. In particular, it is evaluated as having a foundation to expand its research areas into cell therapy, given its experience in research, development, and clinical development of cell-based bioartificial livers.
The division of roles is also clear. Verismo will lead the development of new drug candidates based on the KIR-CAR platform, the core technology for CAR-T therapies, as well as global clinical and business development, centered on the United States. HLB Cell will be responsible for expanding Verismo's technology and pipeline into Asia based on its domestic R&D infrastructure. To this end, it plans to pursue technology transfers and joint development in Asia while leveraging its own R&D capabilities to discover follow-up cell therapy pipelines.
This acquisition also aligns with the HLB Group's business restructuring strategy of reallocating capabilities around core businesses of each affiliate to strengthen growth drivers. Previously, the HLB Group integrated its new drug development capabilities through the merger of HLB and HLB Science, and strengthened its pharmaceutical distribution capabilities through HLB Pharmaceutical's acquisition of Sinhwa Advance. With this acquisition of HLB Cell, the group has embarked on a restructuring to boost its business competitiveness in the cell therapy sector as well.
Brian Kim, CEO of HLB Innovation and Verismo, said, "This acquisition is a strategic decision to maximize synergy by reallocating the group's bio assets and specialized capabilities around core businesses," adding, "By combining Verismo's global new drug development capabilities with HLB Cell's research foundation built since 2009, HLB Innovation will establish its own independent business capabilities in the cell therapy field and continue to expand its business territory into Korea and Asia."
Meanwhile, an official from HLB Therapeutics said, "With the completion of this LPLV, we have completed all patient-related clinical procedures for SEER-2 and entered the final stage of deriving results," adding, "We will do our utmost to ensure the remaining data organization and analysis proceed without a hitch so that top-line results can be confirmed promptly."
[※ This article was written based on materials released by the company, and clinical trial results and new drug development schedules may change depending on future data analysis and regulatory review processes. It does not recommend buying or selling specific stocks or guarantee investment returns. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


